Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.

Mark KriegsmannStephanie RoesslerKatharina KriegsmannMarcus RennerRémi LonguespéeThomas AlbrechtMoritz LoefflerStephan SingerArianeb MehrabiMonika Nadja VogelAnita PathilBruno KöhlerChristoph SpringfeldChristian RuppKarl Heinz WeissBenjamin Goeppert

Published in: BMC cancer (2019)

Selection of appropriate PD-L1 antibodies and careful evaluation of immunohistochemical staining patterns have a significant impact on PD-L1 testing in CCA. Clinical trials are necessary to investigate the putative beneficial effects of PD-L1 targeted immunotherapy in CCA patients.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
big data
electronic health record
cancer therapy
phase ii
deep learning
data analysis
double blind
placebo controlled